The Emerging World of Digital Therapeutics

Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and account for most of the nation’s health care costs. According to report of CDC, in 2018, approximately more than 9% of the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US. Similar trends for high presence of diabetes are prevalent around other geographies of the globe that include Asia Pacific, Europe, Middle East and Africa. For instance, according to IDF Diabetes Atlas published by the International Diabetes Federation in 2017, south-east Asia is home to approximately one-fifth (19%) of the total diabetes population worldwide. According to the report of American College of Cardiology Foundation, in 2018, Coronary heart disease (CHD) was the leading cause of deaths attributable to cardiovascular disease (CVD) in the US, which is followed by stroke (16.8%), high BP (9.4%), heart failure (HF) (9.0%), and other CVDs (17.9%). By 2035, approximately 130 million adults in the US population are projected to have some form of CVD.

Download sample PDF Brochure >> https://bit.ly/3980740

Digital therapeutics help in reducing the costs associated with chronic diseases, by helping an individual or an insurance provider to keep a track of one’s health status as well as track it with the help of digital means. As per American Diabetes Association, the estimated costs of diagnosed diabetes have risen to $327 billion in 2017, including $237 billion in direct medical costs and $90 billion in reduced productivity. This cost can be managed efficiently by including digital therapeutics that are offered by providers to help manage diabetes, can help patients get assistance with disease management and overcome the logistical challenges uncovered by the investigators.

In 2017, the diabetes segment held a largest market share of 26.6% of the digital therapeutics, by application. This segment is also expected to dominate the market in 2025. The growth of the market is primarily attributed to the rising prevalence of diabetes cases across the globe and also the segment is expected to grow with the fastest growth rate of 22.0% during the forecast period, 2018 to 2025.

Asia Pacific (APAC) region during the forecast period. Factors such as, increasing prevalence of the chronic diseases, acceptance of the digital health platforms, developments performed by the market players in the countries such as India, China, Australia and others are likely to propel growth of the market.

Strategic Insights

Product launch/update and partnerships were observed as the most adopted strategy in global digital therapeutics industry. Few of the product approvals and partnerships made by the players in the market are listed below:

2017: In November, Propeller Health and Express Scripts entered into a partnership to provide Propeller’s FDA-cleared digital solutions to Express Scripts to manage asthma or COPD.

2016: In November, Propeller Health received FDA approval for its Propeller platform for use with GSK’s Ellipta inhaler.

2018: In April, Canary Health entered into a partnership with NMRHCA to offer the Better Choices, Better Health (BCBH) digital therapeutics program in New Mexico.

2016: In June, Canary Health partnered with Medtronic to expand their diabetes care offerings with Canary Health's self-management suite for pre-diabetes, diabetes and related comorbidities.

Source: The Insight Partners